Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TMC125 added to darunavir/ritonavir-based ART in treatment-experienced HIV-1 infection
2005-003160-32Phase 3Completed
- Sponsor
- Tibotec
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing TMC125 arm with Placebo arm (2 arms). Primary endpoint: Proportion with undetectable viral load at Week 24. Started Oct 2005; status: completed.
02
Drugs
etravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-003160-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003160-32.